Log In
Print
BCIQ
Print
Print this Print this
 

levodopa/carbidopa/entacapone (ODM-101)

  Manage Alerts
Collapse Summary General Information
Company Orion Corp.
DescriptionOptimized formulation of levodopa plus dopa decarboxylase (DDC) inhibitor and catechol-O-methyl-transferase (COMT) inhibitor
Molecular Target
Mechanism of ActionCatechol-O-methyl-transferase (COMT) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today